Table 1.
Table listing the 127 patents published in the last 25 years concerning CD95 or its cognate ligand CD95L or the entire CD95/CD95L interaction system.
| N° | Publication Id | Publication date | Country | Disease | Approach | Title | Inventors | Ref. |
|---|---|---|---|---|---|---|---|---|
| 1 | WO2003079750 | 2003.10.02 | WO | Autoimmune diseases/inflammatory diseases/cancer | Antibodies | Antagonistic anti-hfas ligand human antibodies and fragments thereof | LANCASTER Joanne Sloan | [350] |
| 2 | US20200102397/WO2017051002 | 2020.04.02/2017.03.30 | WO | Cancer | Antibodies | Anti-cd95l antibody |
GIEFFERS Christian, HILL Oliver, THIEMANN Meinolf et al. |
[221] |
| 3 | WO2015165973 | 2017.03.08 | WO | Cancer | Antibodies | Diagnostic anti-cd95l antibody |
FRICKE, Harald GIEFFERS, Christian SYKORA, Jaromir |
[221] |
| 4 | WO2008080623 | 2016.04.28 | WO | Cancer | Antibodies | Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo |
MARTIN-VILLALBA Ana, KLEBER Susanne, WIESTLER Benedikt et al. |
[325] |
| 5 | US20150274833/EP2920210/WO2014076292 | 2015.10.01/2015.09.23/2014.05.22 | WO | Cancer | Antibodies | Recombinant bispecific antibody binding to cd20 and cd95 |
HERRMANN Andreas, GROSSE-HOVEST Ludger |
[271, 272, 351] |
| 6 | EP2717911/WO2012168259 | 2014.04.16/2012.12.13 | WO | Cancer | Antibodies | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
BENTIRES-ALJ Mohamed, ACETO Nicola, STADLER Michael |
[352] |
| 7 | US20060083738/EP1506237/WO2003097698 | 2006.04.20/2005.02.16/2003.11.27 | WO | Cancer | Antibodies | Treatment of cancer by the use of anti fas antibody |
JOHNSTON Patrick Gerard, LONGLEY Daniel |
[269, 353–355] |
| 8 | WO2010066914 | 2011.10.19 | WO | Others | Antibodies | Remedies for pemphigus containing anti fas-ligand antibodies |
PINCELLI Carlo, MARCONI Alessandra |
[356] |
| 9 | US20030082180/WO2001041803 | 2003.05.01/2001.06.14 | WO | Others | Antibodies | Combination of compounds that inhibit the biological effects of tnf-α and cd95l in a medicament |
KRAMMER Peter, MARTIN-VILLALBA Ana |
[357] |
| 10 | US20110300113/EP2064235/WO2008034608 | 2011.12.08/2009.06.03/2008.03.27 | WO | Others | Antibodies/cells | The death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro |
MARTIN-VILLALBA Ana, CORSINI Nina, LETELLIER Elisabeth et al. |
[358] |
| 11 | WO2010006772 | 2011.08.04 | WO | Inflammatory diseases | Antibodies/fusion proteins | Use of cd95 inhibitors for the treatment of inflammatory disorders |
MARTIN-VILLALBA Ana, LETELLIER Elisabeth, SANCHO-MARTINEZ Ignacio |
[359] |
| 12 | US20170166648/EP3150224/WO2014013036 | 2017.06.15/2017.04.05/2014.01.23 | WO | Others | Antibodies/fusion proteins | Inhibitors of the cd95 signaling pathway for treatment of mds |
FRICKE Harald, FONTENAY Michaela, KUNZ Claudia |
[348, 349] |
| 13 | US20060234968/WO2004071528 | 2006.10.19/2004.08.26 | WO | Others | Antibodies/fusion proteins | Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
MARTIN-VILLALBA Ana, KRAMMER Peter, DEMJEN Deana |
[360] |
| 14 | US20030170244 | 2003.09.11 | US | Cancer/others | Antibodies/fusion proteins | Inhibition of fas signaling |
PLUENNEKE John D, CONNOR Timothy |
[361] |
| 15 | US6846637/WO1999065935 | 2005.01.25/1999.12.23 | WO | Cancer/autoimmune diseases/others | Antibodies/polypeptides | Fas peptides and antibodies for modulating apoptosis | CHIODI Francesca | [362] |
| 16 | WO2016170027 | 2016.10.27 | WO | Inflammatory diseases | Antibodies/polypeptides | Methods and pharmaceutical compositions for the treatment of th17 mediated diseases |
LEGEMBRE Patrick, BLANCO Patrick, FLYNN Robin |
[101] |
| 17 | US20120294856/EP2502069/WO2011058175 | 2012.11.22/2012.09.26/2011.05.19 | WO | Cancer | Antobodies/enzymes/RNA interfering molecules | Compounds inhibiting cd95 signaling for the treatment of pancreatic cancer |
MARTIN-VILALBA Ana, HERHAUS Peter, SANCHO-MARTINEZ Ignacio et al. |
[363] |
| 18 | US20200407728/WO2016069282 | 2020.12.31/2016.05.06 | WO | Autoimmune diseases | Cells | Altering gene expression in modified t cells and uses thereof |
ZHAO Yangbing, REN Jiangtao, LIU Xiaojun, JUNE Carl H. |
[364] |
| 19 | US20150104428/EP2833896/WO2013149211 | 2015.04.16/2015.02.11/2013.10.03 | WO | Autoimmune diseases | Cells | Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation |
SHI Songtao, AKIYAMA Kentaro, CHEN Chider |
[330, 331] |
| 20 | WO2015038665 | 2015.03.19 | WO | Autoimmune diseases/inflammatory diseases | Cells | A composition of stem cells having highly expressed fas ligand |
SHI Songtao, LIU Shiyu, CHEN Fa-ming |
[365] |
| 21 | US20200121719/EP3565888/WO2018129332 | 2020.04.23/2019.11.13/2018.07.12 | WO | Cancer | Cells | Expansion of tumor-infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
LOTZE Michael, T, RITTHIPICHAI Krit |
[277, 366, 367] |
| 22 | EP3569700/WO2011052545 | 2019.11.20/2011.05.05 | WO | Cancer | Cells | Method for producing antigen-specific b-cell population | KITAMURA Daisuke, NOJIMA Takuya | [368] |
| 23 | US20180008670 | 2018.01.11 | US | Cancer | Cells | Chimeric antigen receptor targeting of tumor endothelium |
WAGNER Samuel C., ICHIM Thomas E, MINEV Boris |
[280] |
| 24 | WO2015161276 | 2015.10.22 | WO | Cancer | Cells | Crispr-cas-related methods, compositions and components for cancer immunotherapy | WELSTEAD G. Grant, FRIEDLAND Ari E, MAEDER Morgan L, BUMCROT David A | [369] |
| 25 | WO2014039044 | 2014.13.03 | US | Cancer | Cells | Methods of producing t memory stem-cell populations |
GATTINONI Luca, LUGLI Enrico, ROEDERER Mario, RESTIFO Nicholas P |
[281, 370, 371] |
| 26 | US20040131599/WO2002072798 | 2004.07.08/2002.09.19 | WO | Cancer | Cells | Fas ligand-expressing hematopoietic cells for transplantation |
CIVIN Curt, I, DRACHMAN Daniel, WHARTENBY Katherine, PARDOLL Drew M |
[372] |
| 27 | US20090191167/EP2046351/WO2008014470 | 2009.07.30/2009.04.15/2008.01.31 | WO | Cancer/autoimmune diseases/others | Cells | Adult sertoli cells and uses thereof | WHITE David J | [373] |
| 28 | WO2018227286 | 2018.12.20 | WO | Inflammatory diseases/others | Cells | Allograft tolerance without the need for systemic immune suppression |
NAGY Andras, HARDING Jeffrey, NAGY Kristina |
[374] |
| 29 | WO2018130679 | 2019.11.20 | WO | Cancer | Chemicals | Methods and pharmaceutical compositions for reducing cd95- mediated cell motility |
LEGEMBRE Patrick, VACHER Pierre, POISSONNIER Amanda, BLANCO Patrick |
[101] |
| 30 | US20190084987 | 2019.03.21 | US | Cancer | Chemicals | Small molecule histone methyltransferase suv39h1 inhibitor and uses thereof |
LU Chunwan, LEBEDYEVA Iryna, LIU Kebin |
[301] |
| 31 | US20150343024/EP2931375/WO2014090224 | 2015.12.03/2015.10.21/2014.06.19 | WO | Cancer | Chemicals | Use of active substance combinations for inducing tumor senescence |
RÖCKEN Martin, WIEDER Thomas, HAHN Matthias et al. |
[375] |
| 32 | WO2008036244 | 2008.03.27 | WO | Cancer | Chemicals | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
REED John C, THOMAS Michael P |
[376] |
| 33 | WO2019206834 | 2019.10.31 | WO | Cancer/autoimmune dieases | Chemicals | Compounds and pharmaceutical compositions for reducing cd95-mediated cell motility |
VACHER Pierre, LEGEMBRE Patrick, JEAN Mickael et al. |
[142] |
| 34 | WO2002047728 | 2002.06.20 | WO | Others | Chemicals | Treatment of posterior capsule opacification | ALLAN Bruce Duncan Samuel | [377] |
| 35 | WO2019141862 | 2019.07.25 | WO | Inflammatory diseases | Chemicals/antobodies/fusion proteins/nucleotide complexes | Combination therapeutics |
WALCZAK Henning, TARABORRELLI Lucia, PELTZER Nieves |
[321] |
| 36 | US20090142369 | 2009.06.04 | US | Others | Cosmetic composition | Method for preventing skin-cellular injury by using green algae extract and cosmetic composition containing green algae extract |
SHIH Meng-Han, SHIH Mei-Fen |
[378] |
| 37 | US20080118466 | 2008.05.22 | US | Autoimmune diseases | Drug delivery system | Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers |
HUREZ Vincent Jacques, MICHELSON Seth G, SHODA Lisl Katharine et al. |
[379, 380] |
| 38 | EP0930890/WO1998017305 | 1999.07.28/1998.04.30 | WO | Autoimmune diseases | Drug delivery system | Use of fasl or fasl transfected cd4?+ /fasl?- /th1-cell lines for the treatment of th1/th2 diseases |
HAHNE Michael, TSCHOPP Juerg, DA CONCEICAO-Silva Fatima, SCHROETER Michael |
[381] |
| 39 | US20200046780/EP3592392 | 2020.02.13/2020.01.15 | US/EP | Autoimmune diseases/others | Drug delivery system | Fasl-engineered biomaterials with immunomodulatory function |
SHIRWAN Haval, GARCIA Andres J, YOLCU Esma S et al. |
[136, 382] |
| 40 | US20050214311/EP1478390/WO2003070271 | 2005.09.29/2004.11.24/2003.08.28 | WO | Cancer | Drug delivery system | Novel complexes for inducing an immune response |
SCREATON Gavin R, SIMON Katharina A, GALLIMORE Awen M |
[383] |
| 41 | US20200108117/WO2019246130 | 2020.04.09/2019.12.26 | US | Cancer/others | Drug delivery system | Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertension | SCHIFFMAN Rhett M, SCHEIBLER Lukas | [384] |
| 42 | US20200246432/WO2019040372 | 2020.08.06/2019.02.28 | WO | Others | Drug delivery system | Nitric oxide- and fas ligand- eluting compositions and devices and methods of treatment using same |
KURAL M Hamdi, GUI Liqiong, NIKLASON L Elizabeth, SALTZMAN William Mark |
[385] |
| 43 | WO2019246141 | 2019.12.26 | WO | Others | Drug delivery system | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas-ligand (fasl) inhibitor, a tumor necrosis factor-α (tnf-α) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease | SCHIFFMAN Rhett M, SCHEIBLER Lukas | [384] |
| 44 | WO2019246130 | 2019.12.26 | WO | Others | Drug delivery system | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension | SCHIFFMAN Rhett M, SCHEIBLER Lukas | [384] |
| 45 | US20040096450/WO2000040263 | 2004.05.20/2000.07.13 | WO | Others | Drug delivery system | Methods and compositions for treating diseases associated with increased fas-ligand titers |
FRENCH Lars E, VIARD Isabelle, TSCHOPP Jurg |
[386] |
| 46 | US20190330305/WO2014121085 | 2019.10.31/2014.08.14 | WO | Autoimmune diseases/inflammatory diseases/cancer | Fusion proteins | Pd-l1 and pd-l2-based fusion proteins and uses thereof | TYKOCINSKI Mark L | [387] |
| 47 | EP1481687 | 2004.12.01 | EP | Autoimmune diseases/inflammatory diseases/cancer | Fusion proteins | Use of multimeric ligands of the tnf family with reduced toxicity for treating cell proliferative diseases | ROSAT Jean-Pierre | [294] |
| 48 | US20070269449/WO2004085478 | 2007.11.22/2004.10.07 | WO | Autoimmune diseases/inflammatory diseases/others | Fusion proteins | Cd95-fc fusion proteins | WALCZAK Henning | [388] |
| 49 | EP1214411/WO2001018202 | 2002.06.19/2001.03.15 | WO | Autoimmune diseases/inflammatory diseases/others | Fusion proteins | Flint analog compounds and formulations thereof |
ATKINSON Paul Robert, TIAN Yu, WITCHER Derrick Ryan |
[389–391] |
| 50 | WO2001090382 | 2001.11.29 | WO | Autoimmune diseases/inflammatory diseases/others | Fusion proteins | Fas ligand-fused proteins | TOUMA Jyunko | [392] |
| 51 | US20180318394/EP3313429/WO2016205714 | 2018.11.08/2018.05.02/2016.12.22 | WO | Autoimmune diseases/others | Fusion proteins | Immunomodulation for the long-term prevention and treatment of autoimmune diseases and foreign tissue rejection | SHIRWAN Haval | [382, 393, 394] |
| 52 | US20110081369/EP1250055 | 2011.04.07/2002.10.23 | US/EP | Autoimmune diseases/others | Fusion proteins | Methods of immune modulation with death receptor-induced apoptosis | SHIRWAN Haval | [382, 393, 394] |
| 53 | US20110003385/EP0804561 | 2011.01.06/1997.11.05 | US/EP | Autoimmune diseases/others | Fusion proteins | Regulated transcription of targeted genes and other biological events | CRABTREE Gerald R, SCHREIBER Stuart L, SPENCER David M | [395] |
| 54 | US20090239240/EP2039768 | 2009.09.24/2009.03.25 | US | Autoimmune diseases/others | Fusion proteins | Mutant forms of fas ligand and uses thereof | KETING Chu | [266] |
| 55 | US20180148512/WO2014121093 | 2018.05.31/2014.08.07 | WO | Cancer | Fusion proteins | Fusion proteins that facilitate cancer cell destruction | TYKOCINSKI Mark L | [289] |
| 56 | WO2015197874 | 2017.05.03 | WO | Cancer | Fusion proteins | Combination of cd95/cd95l inhibition and cancer immunotherapy |
KUNZ Claudia, FRICKE Harald, HÖGER Thomas, GAMER Juergen |
[266, 396–398] |
| 57 | US20150297745/EP2897642/WO2014045022 | 2015.10.22/2015.07.29/2014.03.27 | WO | Cancer | Fusion proteins | Agents and methods |
COBBOLD Mark, MILLAR David |
[399] |
| 58 | WO2012170072 | 2014.04.17 | WO | Cancer | Fusion proteins | Engineered antibody-tnfsf member ligand fusion molecules |
GREWAL Iqbal, KHARE Sanjay D, GRESSER Michael, SYED Rashid |
|
| 59 | US20120177575/EP2456468/WO2011010156 | 2012.07.12/2012.05.30/2011.01.27 | WO | Cancer | Fusion proteins | Fas (apo-1,cd95) targeted platforms for intracellular drug delivery |
ATEH Davidson D, MARTIN Joanne E |
[400] |
| 60 | US20110008842 | 2011.01.13 | US | Cancer | Fusion proteins | Chimeric nucleic acids encoding polypeptides comprising cd70 and fas-ligand domains |
PRUSSAK Charles E, KIPPS Thomas J, CANTWELL Mark J |
[401] |
| 61 | EP3406630/US20180186856/WO2014013037 | 2018.11.28/2018.02.22/2014.01.23 | WO | Cancer/autoimmune diseases/inflammatory diseases/others | Fusion proteins | Nucleic acids encoding artificial signal peptides and methods of production thereof |
HILL Oliver, GIEFFERS Christian, THIEMANN Meinolf |
[324, 325, 346, 348, 402] |
| 62 | WO2014013039 | 2014.01.23 | WO | Cancer/autoimmune diseases/inflammatory diseases/others | Fusion proteins | Composition comprising a mixture of cd95-fc isoforms |
HILL Oliver, GIEFFERS Christian, THIEMANN Meinolf |
[324, 325, 402] |
| 63 | WO2013060864 | 2014.09.03 | WO | Cancer/autoimmune diseases/others | Fusion proteins | Chimeric molecule involving oligomerized fasl extracellular domain |
TAUPIN Jean-Luc, DABURON Sophie, MOREAU Jean-François, CAPONE Myriam |
[292, 293] |
| 64 | WO2008025516 | 2011.02.03 | WO | Cancer/inflammatory diseases/others | Fusion proteins | Cd95l or trail fusion proteins |
HILL Oliver, GIEFFERS Christian, THIEMANN Meinolf |
[324, 325, 402] |
| 65 | US20190016782/WO2014106839 | 2019.01.17/2014.07.10 | WO | Cancer/others | Fusion proteins | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
DRANITZKI ELHALEL Michal, SHANI Noam |
[266] |
| 66 | EP2042509/US20070154905 /WO1997003998 | 2009.04.01/2007.07.05/1997.02.06 | WO | Cancer/others | Fusion proteins | Modulators of the function of fas receptors and other proteins |
WALLACH David, BOLDIN Mark, GONCHAROV Tanya, GOLSTEV Yury V |
[403] |
| 67 | WO2007022273 | 2007.02.22 | WO | Cancer/others | Fusion proteins | Vegf-activated fas ligands | QUINN Timothy P | [404, 405] |
| 68 | US20040147447/WO1999066039 | 2004.07.29/1999.12.23 | WO | Cancer/others | Fusion proteins | Tnfr-like protein with death domain |
LU Jian J, GOMES Bruce C, FIELES William E |
|
| 69 | US20110171212 | 2011.07.14 | US | Inflammatory diseases | Fusion proteins | Methods and compositions for preventing radiation-induced pneumonitis |
BELKA Claus HERBST Jörg |
[406] |
| 70 | US20040176279/WO2002060949 | 2002.08.08 | WO | Inflammatory diseases/others | Fusion proteins | Glycoforms a fas-ligand inhibitory protein analog |
JENKINS Nigel, WITCHER Derrick R WROBLEWSKI Victor J |
[407] |
| 71 | US20160340409/EP2621514/WO2012042480 | 2016.11.24/2013.08.07/2012.04.05 | WO | Others | Fusion proteins | Compositions and methods for treatment of hematological malignancies | DRANITZKI ELHALEL Michal | [266] |
| 72 | US20040018170 | 2004.01.29 | US | Others | Fusion proteins | Fas ligand-avidin/streptavidin fusion proteins | SHIRWAN Haval | [382, 393, 394] |
| 73 | EP1097226/WO2000003023 | 2001.05.09/2000.01.20 | WO | Cancer/autoimmune diseases/others | Fusion proteins | Usurpin, a mammalian ded-caspase homologue that precludes caspase-8 recruitment and activation by the cd95 (fas, apo-1) receptor complex |
NICHOLSON Donald, W, RASPER Dita M, XANTHOUDAKIS Steve, ROY Sophie |
[408] |
| 74 | EP3337509/US20170051352 | 2018.06.27/2017.02.23 | US/EP | Autoimmune diseases | Method | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
HAKONARSON Hakon, KAO Charlly, CARDINALE Christopher et al. |
[409] |
| 75 | US20160194714 | 2016.07.07 | US | Autoimmune diseases | Method | Biomarkers for predicting relapse in multiple sclerosis |
RUS Horea TEGLA Cosmin |
[306–309] |
| 76 | US20160208332 | 2016.04.07 | US | Autoimmune diseases | Method | Diagnosis and prognosis of multiple sclerosis |
RUS Horea CUDRICI Cornelia TEGLA Cosmin |
[306–309] |
| 77 | US20100285600/EP1891233/WO2006116602 | 2010.11.11/2008.02.27/2006.11.02 | WO | Autoimmune diseases | Method | Markers associated with the therapeutic efficacy of glatiramer acetate |
LANCET Doron BECKMANN Jacques AVIDAN Nili et al. |
[410] |
| 78 | US20090074870/WO2002002751 | 2009.03.19/2002.01.10 | WO | Autoimmune diseases/others | Method | Alteration of cell membrane with fasl | SHIRWAN Haval | [411] |
| 79 | WO2015107105 | 2016.11.23 | WO | Cancer | Method | Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation | FRICKE Harald | [297–299] |
| 80 | WO2015104284 | 2016.11.16 | WO | Cancer | Method | Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination |
LEGEMBRE Patrick, SEGUI Bruno, LEVADE Thierry, MICHEAU Olivier |
[296, 412] |
| 81 | WO2014118317 | 2015.12.31 | WO | Cancer | Method | Methods for predicting and preventing metastasis in triple-negative breast cancers |
LEGEMBRE Patrick, MALLETER Marine, TAUZIN Sébastien et al. |
[141] |
| 82 | US20150098924/WO2006037762 | 2015.04.09/2006.04.13 | WO | Cancer | Method | Method for ex-vivo purging in autologous transplantation |
DUPUIS Marc, GREANEY Peter, DUCHOSAL Michel |
[413] |
| 83 | EP1668360/US20050069963 | 2006.06.14/2005.03.31 | US/EP | Cancer | Method | Multifactorial assay for cancer detection |
LOKSHIN Anna E. GORELIK Elieser |
[414] |
| 84 | US20050158807/WO2003056340 | 2005.07.21/2003.07.10 | WO | Cancer | Method | Fadd proteins, phosphorylated p38-mapk and fasl as tumor markers |
CHIOCCHIA Gilles, TOURNEUR Lea, FEUNTEUN Jean et al. |
[415] |
| 85 | WO2005053739 | 2005.06.16 | WO | Cancer | Method | Combination therapy |
JOHNSTON Patrick G, LONGLEY Daniel |
[416] |
| 86 | EP1127075/WO2000027883 | 2001.08.29/2000.05.18 | WO | Cancer | Method | A method of treating tumors using fas-induced apoptosis |
DONG Jian-Yun NORRIS James S |
[417] |
| 87 | WO2001048238 | 2001.07.05 | WO | Cancer | Method | Chemotherapeutant screening method |
KRAMMER Peter, EICHHORST Sören, LI-WEBER Min, MÜLLER-SCHILLING Martina |
[418] |
| 88 | WO1999003998 | 1999.01.28 | WO | Cancer | Method | Methods and compositions for tumor reduction | NABEL Gary J | [419] |
| 89 | US6153385/WO1997020067 | 2000.11.28/1997.06.05 | WO | Cancer/autoimmune diseases/others | Method | Process for detecting the expression of cd95 ligand in cells |
DEBATIN Klaus-Michael HERR Ingrid |
[420] |
| 90 | EP0876503/WO1997020064 | 1998.11.11/1997.06.05 | WO | Cancer/autoimmune diseases/others | Method | Process for assessing the activity of drugs |
DEBATIN Klaus-Michael, FRIESEN Claudia, KRAMMER Peter, HERR Ingrid |
[420] |
| 91 | EP0689600/WO1994020625 | 1996.01.03/1994.09.15 | WO | Cancer/others | Method | Process to induce the death of tumor cells | WONG Grace H W | [421] |
| 92 | WO1999003999 | 1999.01.28 | WO | Inflammatory diseases | Method | Methods and compositions for inhibiting the pro-inflammatory response |
NABEL Gary J, CHEN Jian-Jun |
[422] |
| 93 | US20020127233 | 2002.09.12 | US | Inflammatory diseases/cancer/others | Method | Method for inhibiting inflammation in immune privileged sites using fas-ligand fragments |
ZHU Bing, CYNADER Max S, PATY Donald W, LUO Liqing |
[423] |
| 94 | US20180369380 | 2018.12.27 | US | Others | Method | Methods and compositions for treating conditions of the eye |
GRAGOUDAS Evangelos S, POULAKI Vasiliki, MILLER Joan W |
[424] |
| 95 | US20140045198/EP2678688 /WO2012113760 | 2014.02.13/2014.01.01/2012.08.30 | WO | Others | Method | Method of predicting the evolution of a patient suffering of a neurovascular disease |
MONTANER VILLALONGA Joan, ROSELL NOVEL Anna, NAVARRO SOBRINO Miriam |
[357, 425] |
| 96 | US20110294690/EP2338058/WO2010031821 | 2011.12.01/2011.06.29/2010.03.25 | WO | Others | Method | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof | MONTANER VILALLONGA Joan | [357, 425] |
| 97 | US20060241150/WO2005000405 | 2006.10.26/2005.01.06 | WO | Others | Method | P38 kinase inhibitor compositions and methods of use |
WEINER David B, MUTHUMANI Karuppiah |
[426] |
| 98 | WO2006077232 | 2006.07.27 | WO | Others | Method | Multimeric soluble fas-ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation |
DUPUIS Marc, DEMOTZ Stéphane, GREANEY Peter et al. |
[413, 427] |
| 99 | US20050129684 | 2005.06.16 | US | Others | Method | Methods for preserving the viability of photoreceptor cells by anti-fas-ligand/anti-fas-receptor antibodies |
ZACKS David, MILLER Joan W |
[428] |
| 100 | US20030224403 | 2003.12.04 | US | Others | Method | Lethal toxin cytopathogenicity and novel approaches to anthrax treatment |
POPOV Serguei G, CARRON Edith G, CARDWELL Jennifer |
[429] |
| 101 | US6524821/WO2000007618 | 2003.02.25/2000.02.17 | WO | Others | Method | Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
LANGELIER Yves, MASSIE Bernard |
[430] |
| 102 | US6485929/WO1999036091 | 2002.11.26/2000.07.22 | WO | Others | Method | Method for inhibiting cd95-independent apoptosis in aids |
KRAMME, Peter H, BERNDT Christina |
[431] |
| 103 | WO2015189236 | 2015.12.17 | WO | Cancer | Method | Methods and pharmaceutical compositions for reducing cd95-mediated cell motility |
LEGEMBRE Patrick, COUNILLON Laurent, LAGADIC-GOSSMANN Dominique |
[295] |
| 104 | US2003011865/WO2000059538 | 2002.06.06/2000.10.12 | WO | Autoimmune diseases/others | Nucleotide complexe | Antigen-specific induction of peripheral immune tolerance |
AUGUST Thomas J. LEONG Kam W. GEORGANTAS Robert |
[432] |
| 105 | WO2001051503 | 2001.07.19 | WO | Cancer | Nucleotide complexe | Polynucleotides for inhibiting metastasis and tumor cell growth | BARBERA-GUILLEM Emilio | [433] |
| 106 | US20020042064/EP1121438/WO2000023583 | 2002.04.11/2001.08.08/2000.04.27 | WO | Cancer/autoimmune diseases/others | Nucleotide complexe | P53 binding areas |
KRAMMER Peter, MÜLLER-SCHILLING Martina, OREN Moshe |
[251] |
| 107 | US20040033979/EP1176965 | 2004.02.19/2002.02.06 | US/EP | Cancer/autoimmune diseases/inflammatory diseases | Nucleotide complexe | Antisense modulation of fas mediated signaling |
DEAN Nicholas M, MARCUSSON Eric G, WYATT Jacqueline, ZHANG Hong |
[434] |
| 108 | US20030119776/EP1313853 | 2003.06.26/2003.05.28 | US/EP | Cancer/autoimmune diseases/others | Nucleotide complexe | Modulation of fas and fasl expression |
PHILLIPS Nigel C, FILION Mario C |
[435] |
| 109 | US20070190607/WO2001058953 | 2007.08.16/2001.08.16 | WO | Autoimmune diseases | Polypeptides | Inhibitors of pre-ligand assembly doman and function of the tumor necrosis factor receptor family |
LENARDO Michael J, CHAN Francis Ka-Ming, SIEGEL Richard M |
[36] |
| 110 | US7097972/WO1996025501 | 2006.08.29/1996.08.22 | WO | Autoimmune diseases/inflammatory diseases/cancer | Polypeptides | Method and composition for regulating apoptosis | DIXIT,Vishva M | [436] |
| 111 | US20120245081 | 2012.09.27 | US | Autoimmune diseases/inflammatory diseases/others | Polypeptides | Fas peptide mimetics and uses thereof |
GREENE Mark I, MURALI Ramachandran, HASEGAWA Akihiro |
[437] |
| 112 | US20070184522/EP1737483/WO2005117940 | 2007.08.09/2007.01.03/2005.12.15 | WO | Autoimmune diseases/others | Polypeptides | Cell death modulation via antagonists of fasl and fas activation |
ZARNEGAR Abdolreza, DEFRANCES Marie C, ZOU Chun-Bin |
[438] |
| 113 | US6451759/WO1999036079 | 2002.09.17/1999.07.22 | WO | Autoimmune diseases/others | Polypeptides | Noncleavable fas ligand |
KANG, Sang-Mo BRAAT, Dries BAEKKESKOV, Steinunn STOCK, Peter, G. |
[439] |
| 114 | WO2020132465 | 2020.06.25 | WO | Cancer | Polypeptides | Methods and compositions related to therapeutic peptides for cancer therapy |
BECKER Lev, CUI Chang |
[286] |
| 115 | EP2102234/WO2008067305 | 2009.09.23/2008.05.06 | EP | Cancer | Polypeptides | Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain |
WAGNER Thomas E, WEI,Yanzhang |
[440] |
| 116 | US20190085050/WO2015158810 | 2019.03.21/2015.10.22 | WO | Cancer/autoimmune diseases/inflammatory diseases | Polypeptides | Polypeptides and uses thereof for reducing cd95-mediated cell motility |
LEGEMBRE Patrick, VACHER Pierre, SANSEAU Doriane et al. |
[146] |
| 117 | EP1225908/WO2001028582 | 2002.07.31/2001.04.26 | WO | Cancer/inflammatory diseases/others | Polypeptides | Therapeutic applications of flint polypeptides |
BUMOL Thomas F COHEN Fredric J |
|
| 118 | US20100041596/WO2007002633 | 2010.02.18/2007.01.04 | WO | Inflammatory diseases | Polypeptides | Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (plad) of tumor necrosis factor receptors |
LENARDO Michael, DENG Guo-Min, CHAN Francis Ka-Ming, ZHENG Lixen |
[441] |
| 119 | US20100041596/WO2009027350 | 2017.08.31/2009.03.05 | WO | Inflammatory diseases/others | Polypeptides | Use of sco-spondin peptides for inhibiting or preventing neuronal apoptosis mediated by cell death receptor ligands |
MEINIE, Annie, LALLOUE Fabrice, JAUBERTEAU Marie-Odile |
[442] |
| 120 | US20130288979/EP2982685 /WO2012066103 | 2017.11.14/2016.02.10/2012.05.24 | WO | Others | Polypeptides | Inhibitors of apoptosis and uses thereof |
BARRERE Stéphanie, NARGEOT Joël, LEBLEU Bernard et al. |
[443] |
| 121 | US20010018416 | 2001.08.30 | US | Others | Polypeptides | Compositions and methods for treating hepatitis-c |
SLESAREV Vladimir I, DIMITROV Todor |
[444] |
| 122 | US20060089491 | 2004.06.07 | US | Cancer | Polypeptides/nucleotide complexes | Fas-ligand derived polypeptides |
NAGATA Shigekazu, SUDA Takashi, TAKAHASHI Tomohiro, NAKAMURA Norio |
[445] |
| 123 | US20090169599 | 2009.07.02 | US | Others | Reprogrammed virus | Scientifically modulated and reprogrammed treatment (smart) fas/fasl virus technology intended to neutralize t-helper cells infected with the human immunodeficiency virus |
SCHEIBER Lane Bernard SCHEIBER II Lane Bernard |
|
| 124 | EP2355833/US20100324116 | 2011.08.17/2010.12.23 | US/EP | Cancer | RNA interfering molecules | Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells |
KRUSE Carol, TRITZ Richard |
[283] |
| 125 | US20050119212 | 2004.06.18 | US | Autoimmune diseases/others | RNA interfering molecules | Rna interference mediated inhibition of fas and fasl gene expression using short interfering nucleic acid (sina) |
HAEBERLI Peter, MCSWIGGEN James |
[446] |
| 126 | US20070004666 | 2007.01.04 | US | Cancer/autoimmune diseases/others | Transcription factors | Methods for modulating apoptotic cell death |
LASHAM Annette, WATSON James D |
[447, 448] |
| 127 | WO1998008965 | 1998.03.05 | WO | Autoimmune diseases/others | Transcription factors/nucleotide complexes | Cd95 regulatory gene sequences and transcription factors |
WATSON James, D, RUDERT Fritz |
[447, 448] |
The source of information used is the Patentscope of the WIPO IP Portal and the search was carried out by selecting only the patents published in the United States Patent Office and European Patent Office. Furthermore, the selection was made using keywords and selecting only the patents with these keywords in the title of the publication or the corresponding abstract on the front page. The keywords used are CD95, CD95L, CD95 ligand, Fas, FasL, Fas ligand.